欧盟批准AstraZeneca对慢性淋巴细胞白血病的计算结果,显示试验结果较好。 EU approves AstraZeneca's Calquence for chronic lymphocytic leukaemia, showing better outcomes in trials.

欧盟已批准使用AstraZeneca的Calquence与venetoclax一起用于治疗未经治疗的慢性淋巴细胞白血病 (CLL) 的成年人. The European Union has approved AstraZeneca's Calquence, used with venetoclax, to treat adults with untreated chronic lymphocytic leukaemia (CLL). 根据第三阶段试验的结果,与标准治疗相比,这种结合表明,与标准治疗相比,无累进性存活率较好。 Based on a Phase III trial, the combination showed better progression-free survival rates compared to standard treatments. 这种新的治疗方案可能有助于减少CLL病人的长期副作用和药物抗药性。 This new regimen may help reduce long-term side effects and drug resistance in CLL patients.